REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • August 8th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Agreement (“Agreement”) is made and entered into as of July 11, 2022, by and between Reata Pharmaceuticals, a Delaware corporation (the “Company”), and Steven W. Ryder, M.D. (“Indemnitee”).
SEVENTH SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study in JapanExclusive License and Supply Agreement • August 8th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Seventh Supplement (herein so called), effective as of February 28, 2022 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement”), is by and between Reata Pharmaceuticals Holdings, LLC, a limited liability company organized and existing under the laws of Delaware, USA, with an address at 5320 Legacy Drive, Plano, Texas 75024 (“Reata”), as assignee of the Original Agreement from Reata Pharmaceuticals, Inc., a Delaware corporation and the original signatory to the Original Agreement, as assignor (“Reata Pharmaceuticals”), and Kyowa Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.
